Does mouthrinsing and gargling with povidone iodine and hydrogen peroxide reduce the number of SARS-CoV-2 viruses in patients with no and mild symptoms?

ISRCTN ISRCTN18356379
DOI https://doi.org/10.1186/ISRCTN18356379
Submission date
18/01/2022
Registration date
03/02/2022
Last edited
20/12/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Coronavirus disease 2019 (COVID-19) can spread rapidly. During surgical procedures in the mouth, the risk of transmitting SARS-CoV-2 virus is high. The American Dental Association (ADA) and Centers for Disease Control and Prevention (CDC) recommend mouthrinsing with 1.5% hydrogen peroxide or 0.2% povidone iodine to reduce the risk of transmission by reducing the number of viruses in mouth and throat. This study aims to analyse if mouthrinsing and gargling with 1% povidone iodine, 0.5% povidone iodine, 3% hydrogen peroxide, 1.5% hydrogen peroxide and water will make any difference to the number of viruses.

Who can participate?
Adults 19 - 60 years old confirmed positive of SARS-CoV-2, diagnosed for less than three days at Persahabatan Central General Hospital during 1st July – 30th September 2021 with no or mild symptoms.

What does the study involve?
Participants were given mouthrinsing and gargling education through video conference, and mouthrinse that had been repackaged. Participants would need to perform mouthrinsing for 30 seconds in the mouth and gargling and 30 seconds in the back of the throat with 15 mL of mouthrinse 3 times a day for 5 days. The mouthrinsing and gargling activity was carried out in the self-isolation room of each research subject by using video conference. Participants were subjected to RT-PCR test on day 1, day 3 and day 5 after the mouthrinsing and gargling intervention.

What are the possible benefits and risks of participating?
The mouthrinsing and gargling procedures with povidone iodine or hydrogen peroxide were likely to benefit participants by reducing the numbers of viruses in the upper respiratory tract. Furthermore, this study allows future benefits in reducing SARS-CoV-2 transmission during oral and maxillofacial surgery if the mouthrinsing and gargling procedures are recommended and implemented.

Where is the study run from?
The study was run by Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Universitas Indonesia, and took place Persahabatan Central General Hospital (Indonesia)

When is the study starting and how long is it expected to run for?
June 2021 to October 2021

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Lilies Dwi Sulistyani, lilies.dwi@ui.ac.id

Contact information

Dr Lilies Dwi Sulistyani
Principal Investigator

Department of Oral and Maxillofacial Surgery, Faculty of Dentistry
Universitas Indonesia
Salemba Raya IV No.5
Kenari
Senen
Central Jakarta
10430
Indonesia

ORCiD logoORCID ID 0000-0001-5542-6787
Phone +62 81293784268
Email lilies.dwi@ui.ac.id

Study information

Study designInterventional single centre single blind randomized parallel trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleThe evaluation of povidone iodine and hydrogen peroxide mouthrinsing and gargling on CT value of SARS-CoV-2: a randomized controlled trial in asymptomatic and mild symptomatic patients
Study hypothesisThere is an effect of mouthrinsing and gargling with 1% and 0.5% povidone iodine, as well as 3% and 1.5% hydrogen peroxide on the CT value of RT-PCR SARS-CoV-2.
Ethics approval(s)Approved 16/06/2021, Persahabatan Central General Hospital (Jl. Persahabatan Raya No.1, RT.16/RW.13, Rawamangun, Kec. Pulo Gadung, Kota Jakarta Timur, DKI Jakarta 13230 Indonesia; +62 (021) 22472222; info@rsuppersahabatan.co.id), ref: 68.A.1/KEPK-RSUPP/11/2021
ConditionCOVID-19 (SARS-CoV-2 infection)
InterventionResearch subjects were given mouthrinsing and gargling protocol education through video conference and given mouthrinse that had been repackaged. The 1% povidone iodine group rinsed with BETADINE® Mouthwash and Gargle solution. The 3% hydrogen peroxide group rinsed with a solution from OneMed™. The group of 0.5% povidone iodine and 1.5% hydrogen peroxide rinsed with a diluted solution of 1% iodine povidone BETADINE® Mouthwash and Gargle and 3% hydrogen peroxide OneMed™ added with sterile distilled water with the formula Volume1 x Concentration1=Volume2 x Concentration2.
There were two intervention groups and one control group:
- Intervention 1: 1% povidone iodine
- Intervention 2: 0.5% povidone iodine
- Intervention 3: 3% hydrogen peroxide
- Intervention 4: 1.5% hydrogen peroxide
- Control: mineral water
Research subjects performed mouthrinsing for 30 seconds in the oral cavity and gargling and 30 seconds in the back of the throat with 15 mL of mouthrinse 3 times a day for 5 days. The mouthrinsing and gargling activity was carried out in the self-isolation room of each research subject by using video conference.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)1% povidone iodine BETADINE®, 3% hydrogen peroxide OneMed™
Primary outcome measureViral load measured using CT value of the RT-PCR examination on day 1, day 3 and day 5 after the mouthrinsing and gargling intervention
Secondary outcome measuresThere are no secondary outcome measures
Overall study start date16/06/2021
Overall study end date30/10/2021

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants75
Total final enrolment69
Participant inclusion criteria1. Patients of Persahabatan Central General Hospital, (COVID-19 national referral centre)
2. Patients infected with SARS-CoV-2 and identified through RT-PCR with positive results at Persahabatan Central General Hospital during 1st July – 30th September 2021 with CT values ≤ 30
3. Asymptomatic patients or with mild symptoms
4. Patients being diagnosed with COVID-19 for less than three days
5. Aged 19 - 60 years old
Participant exclusion criteria1. Patients not willing to be research subjects
2. Patients with comorbid and thyroid diseases
3. Pregnant patients
4. Patients routinely consumed lithium drugs
5. Patients undergoing radioactive iodine treatment
6. Patients allergic to povidone iodine and hydrogen peroxide
Recruitment start date01/07/2021
Recruitment end date30/09/2021

Locations

Countries of recruitment

  • Indonesia

Study participating centre

Persahabatan Central General Hospital
Persahabatan Raya No.1, RT.16/RW.13, Rawamangun, Pulo Gadung
East Jakarta
13230
Indonesia

Sponsor information

Universitas Indonesia
University/education

Oral and Maxillofacial Surgery Department
Faculty of Dentistry
Jawa Barat
16424
Indonesia

Phone +62 21 3914132
Email oralmaxillofacialsurgery@ui.ac.id
Persahabatan Central General Hospital
Hospital/treatment centre

Rawamangun
Kec. Pulo Gadung
Kota Jakarta Timur
Daerah Khusus Ibukota
Jakarta
13230
Indonesia

Email rsupp_labmikro@yahoo.com

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date01/09/2022
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe datasets generated during and/or analysed during the current study are not expected to be made available due to the confidentiality of the patient’s data policy from Persahabatan Central General Hospital.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 01/11/2022 20/12/2022 Yes No

Editorial Notes

20/12/2022: Publication reference added.
02/02/2022: Trial's existence confirmed by Persahabatan Central General Hospital.